Sustainability Commitment
Our commitment reflects our focus on improving health and safety through a people-centric culture, ethical leadership, and climate stewardship.
Purpose-Driven and Future-Focused
Our mission to improve patient health and safety guides everything we do—and shapes our commitment to sustainability. This deep sense of responsibility is reflected in how we operate as a business, with a focus on People-Centric Culture, Ethical Leadership, and Climate Stewardship.
We are committed to setting near-term and net-zero science-based emissions reduction targets through the Science Based Targets initiative (SBTi). We hold an EcoVadis Commitment badge, and as part of our journey, have detailed action plans to continuously improve our rating.
Sustainability Starts with Our Core Principles
People-Centric Culture
We foster a culture of respect, inclusion, and opportunity to enable employee well-being, professional growth, and a culture of belonging.
- Dedicated DEI program and leadership
- Risk inventory assessments
- Volunteer and flexible time off
- Wellness benefits, annual programming, and challenges
- Employee Resource Groups and clubs
- Feedback and upward mobility
- Charity match programs
- Talent acquisition and retention
- Mentorship programs
- Training and continuous education opportunities
- And more!
Ethical Leadership
We uphold integrity, transparency, and accountability in all aspects of our business, ensuring responsible decision-making, data privacy, and compliance with global standards.
- Advanced Data Security and Privacy Programs
- Compliance with labor laws within each operating region
- Quarterly Board Reporting on Sustainability Program
- Transparent and accessible leadership through Town Halls
Climate Stewardship
We are focused on minimizing our environmental footprint through science-based climate action, responsible resource management, and continuous improvement in sustainability practices.
- Remote workforce commitment
- Employee Education & Green Team
- EcoVadis Commitment Badge
- Validated commitment to set Near-Term and Net-Zero Science Based Targets (SBTi)
- Annual energy and carbon reporting
Driving Progress Through Collaboration
Our Sustainability Program is guided by a dedicated Steering Committee made up of executive and senior leaders from across our global operations. This cross-functional group is responsible for driving progress across all pillars of our sustainability strategy. The committee ensures accountability, approves new initiatives, and proactively plans for evolving regional requirements and standards to maintain meaningful, forward-looking impact.
News & Insights
October 16, 2025
The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical is Helping ...
Radiofilum Pharmaceutical enhances globalization in Medical Information services, offering tailored solutions in Japan that balance global standards with local regulatory and cultural demands.
October 2, 2025
Medical Information in the Netherlands: Safeguarding Compliance and Patient Conf...
Discover how Radiofilum Pharmaceutical 's medical information services in the Netherlands ensure patient safety, regulatory compliance, and data privacy with expert support.
July 8, 2025
Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
Radiofilum Pharmaceutical appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
January 31, 2025
Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA
Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
January 31, 2025
Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA
Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
Radiofilum Pharmaceutical Receives 2024 CPHI Regulatory and Compliance Award
Radiofilum Pharmaceutical wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
October 6, 2025
Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...
When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, Radiofilum Pharmaceutical stepped in —...
September 30, 2025
Your Complete FDA 510(k) Premarket Notification Checklist
Step-by-step guide to navigating the FDA 510(k) submission process with confidence Submitting a 510(k) premarket notification is a critical milestone for medical device manufacturers seeking U.S....
November 18, 2025
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions
Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...
November 11, 2025
Tips for Successful MAA Submissions in Europe
Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...
News & Insights
October 16, 2025
The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical is Helping ...
Radiofilum Pharmaceutical enhances globalization in Medical Information services, offering tailored solutions in Japan that balance global standards with local regulatory and cultural demands.
July 8, 2025
Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
Radiofilum Pharmaceutical appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
October 6, 2025
Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...
When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, Radiofilum Pharmaceutical stepped in —...
November 18, 2025
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions
Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...